Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15073971 | 0.84 | AXL (0.48) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL15074188 | 0.82 | AXL (0.42) | AXLTTKADORA2APLAUMAPK1 | |
| SCHEMBL20657714 | 0.79 | AXL (0.47) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL19171737 | 0.79 | FGFR1 (0.40) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL20657456 | 0.73 | BRD4 (0.40) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL15074148 | 0.73 | AXL (0.48) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL22894666 | 0.71 | AXL (0.39) | AXLTTKADORA2AMAPK1CCNA2 | |
| SCHEMBL15507821 | 0.71 | ALDH1A1 (0.59) | AXLTTKAURKAAURKBINCENP | |
| SCHEMBL17234683 | 0.71 | CLK2 (0.40) | AXLTTKADORA2AMAPK1CCNA2 | |
| SCHEMBL29061506 | 0.70 | PIM1 (0.51) | TTKAURKAAURKBINCENPLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794613-B1 | CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-9399645-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-9399645-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| WO-2013091096-A1 | CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | MCM3, REV1, POLR2E | AXL 2324/4885TTK 3562/4885AURKA 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.